【摘要】：為了探討阿替普酶聯(lián)合丁苯酞治療超早期腦梗死的臨床效果,以及聯(lián)合用藥用患者預(yù)后的相關(guān)影響,本研究選擇本院100例超早期腦梗死的患者進(jìn)行觀察分析,對(duì)照組在常規(guī)治療基礎(chǔ)上加用阿替普酶靜脈溶栓,觀察組在對(duì)照組基礎(chǔ)上加用丁苯酞靜滴,觀察并比較兩組的神經(jīng)缺損程度(NIHSS評(píng)分)和臨床療效。研究發(fā)現(xiàn),相較治療前,兩組的NIHSS評(píng)分在治療后6 h、24 h和7 d均較低(#p0.05),觀察組低于對(duì)照組(▲p0.05);觀察組的臨床總有效率為88%,高于對(duì)照組的總有效率70%(▲p0.05)。由此可見,阿替普酶聯(lián)合丁苯酞治療超早期腦梗死具有良好的臨床療效,能有效改善患者神經(jīng)缺損狀況,且安全性高。
[Abstract]:In order to investigate the clinical effect of atexin combined with butylphthalide in the treatment of ultra-early cerebral infarction and the related effects on the prognosis of patients with ultra-early cerebral infarction, 100 patients with ultra-early cerebral infarction in our hospital were selected for observation and analysis. On the basis of routine treatment, the control group was treated with atexin intravenous thrombolysis, and the observation group was treated with butylphthalein intravenously on the basis of the control group. The degree of nerve defect (NIHSS score) and clinical efficacy were observed and compared between the two groups. The results showed that the NIHSS scores of the two groups were lower at 24 h and 7 d after treatment than those before treatment (# p0.05), while those in the observation group were lower than those in the control group (鈮，

本文編號(hào)：2494902